

Anti-obesity Drugs Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Prescription and OTC), Drug Class (GLP-1 Agonist, Lipase Inhibitors, MC4R agonist, and others), Application (Appetite Suppression, Inhibition of Fat Absorption/Digestive Enzymes, Metabolic Enhancement, and Combination), Route of Administration (Oral and Parenteral), and Distribution Channel (Hospital Pharmacies, Online Channel, and Retail Pharmacies), and Geography

<https://marketpublishers.com/r/A13C6496AF0CEN.html>

Date: June 2025

Pages: 316

Price: US\$ 4,450.00 (Single User License)

ID: A13C6496AF0CEN

Abstracts

According to our new research study on “Anti-obesity Drugs Market Forecast to 2031 –Global Analysis – by Type, Drug Class, Route of Administration, Application, Distribution Channel, and Geography,” the market is anticipated to grow from US\$ 15.85 billion in 2024 and is projected to reach US\$ 177.27 billion by 2031; it is expected to register a CAGR of 35.3% during 2025–2031. Mounting prevalence of obesity and increased awareness and demand for weight management solutions are contributing to the growing anti-obesity drugs market size. However, the side effects and safety concerns hamper the anti-obesity drugs market growth. Further, precision medicine and personalized anti-obesity drug regimens is expected to bring in new anti-obesity drugs market trends in the coming years.

In terms of revenue, North America dominated the market in 2024. It is estimated to dominate the global market during the forecast period. The US is the largest market for

anti-obesity drugs in the world. Chronic wounds associated with diabetes include foot, venous, and pressure ulcers. According to The International Journal of Tissue Repair and Regeneration, active or healed venous ulcers occur in 1% of the US population. As per the National Diabetes Statistics Report 2020, a publication of the Centers for Disease Control and Prevention (CDC), 34.2 million people of all ages in the US have diabetes, and ~1 million diabetics develop a foot ulcer each year, while 6-7 million diabetes patients develop ulcers in their lifetime. Thus, the rising incidence of diabetes and chronic wounds leads to an increase in demand for wound dressing and contributes to the anti-obesity drugs market growth during the forecast period. Companies in the US are focused on expanding their presence by adopting organic and inorganic strategies. In October 2021, Medline Industries announced an investment of US\$ 77.5 million to build a new distribution center in Kansas.

Anti-obesity Drugs Market Analysis

Expansion in Emerging Economies to Provide Market Opportunities in Future

According to a Lancet study published in July 2023, approximately 450 million adults in India are expected to be overweight or obese by 2050. In 2021, more than half of the world's adults who were classified as overweight or obese lived in India, with 180 million affected individuals; China, with 402 million; Brazil, with 88 million; Russia, with 71 million; Mexico, with 58 million; Indonesia, with 52 million; and Egypt, with 41 million.

According to the World Obesity Federation, Vietnam, Indonesia, and Bangladesh are experiencing rising obesity prevalence, with a rate of 6–9% in recent decades. The mounting prevalence of obesity in emerging countries due to urbanization, sedentary lifestyles, and dietary changes has increased the demand for anti-obesity drugs. A large segment of the population remains undiagnosed or untreated, offering an underpenetrated market for pharmaceutical companies to introduce new therapies and expand their reach. Eli Lilly is preparing to launch its weight-loss and diabetes drug, tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity), in India, Brazil, and Mexico by 2026.

Brazil is enhancing healthcare infrastructure and obesity management programs, fostering a supportive environment for the introduction and reimbursement of new anti-obesity medications. In April 2024, Brazil opened a laboratory in Hortolândia, São Paulo State, dedicated to producing medications for diabetes and obesity, including liraglutide, an active ingredient found in Ozempic. The EMS-operated plant will also produce semaglutide, a key ingredient in Ozempic, which has a patent valid until March 2026

and is already under review by Agência Nacional de Vigilância Sanitária (ANVISA). With an investment of R\$60 million (~US\$ 10.93 million), this facility is the first of its kind in Brazil and supports the federal government's Health Economic-Industrial Complex initiatives.

According to the World Economic Forum, initial access to anti-obesity medications may be limited to private markets and out-of-pocket payments. Still, future insurance coverage and generic versions in middle-income countries could improve the accessibility of these medications. Thus, the rising obesity rates, supportive government initiatives, and product innovations are expected to create future growth opportunities for the market in emerging countries.

Anti-obesity Drugs Market Report Segmentation Analysis

Key segments that contributed to the derivation of the anti-obesity drugs market analysis are type, drug class, route of administration, application, and distribution channel.

Based on type, the anti-obesity drugs market is bifurcated into prescription and OTC. The prescription segment held relatively larger share of the market in 2024.

By drug class, the anti-obesity drugs market is segmented into GLP-1 agonists, lipase inhibitors, MC4R agonists, and others. The GLP-1 Agonist segment held the largest share of the market in 2024. GLP-1 agonists segment further subsegmented into Semaglutide, Liraglutide, Tirzepatide.

Based on application, the anti-obesity drugs market is categorized into appetite suppression, inhibition of fat absorption/digestive enzymes, metabolic enhancement, and combination. The appetite suppression segment held a largest share of the market in 2024.

In terms of route of administration, the anti-obesity drugs market is bifurcated into oral and parenteral. The oral segment dominated the market in 2024.

Per distribution channel, the anti-obesity drugs market is categorized into hospital pharmacies, online channel, and retail pharmacies. The hospital pharmacies segment dominated the market in 2024.

Anti-obesity Drugs Market: Competitive Landscape and Key Developments

Novo Nordisk AS, Eli Lilly and Co, GSK Plc, Rhythm Pharmaceuticals Inc, Currax Pharmaceuticals LLC., VIVUS LLC, AdvaCare Pharma USA LL, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, and F. Hoffmann-La Roche Ltd are among the key companies operating in the anti-obesity drugs market.

The World Health Organization, World Obesity Atlas, The U.S. Food and Drug Administration, The Lancet Journal, World Obesity Federation, World Economic Forum, Centers for Disease Control and Prevention (CDC), the International Diabetes Federation (IDF), the Organization for Economic Co-operation and Development (OECD) are primary and secondary sources referred to while preparing the anti-obesity drugs market report.

Reason to buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the anti-obesity drugs market.

Highlights key business priorities in order to assist companies to realign their business strategies.

The key findings and recommendations highlight crucial progressive industry trends in the anti-obesity drugs market, thereby allowing players across the value chain to develop effective long-term strategies.

Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.

Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

The List of Companies - Anti-obesity Drugs Market

Novo Nordisk AS

Eli Lilly and Co

GSK Plc

Rhythm Pharmaceuticals Inc

Currax Pharmaceuticals LLC.

VIVUS LLC

AdvaCare Pharma USA LL

Teva Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd

F. Hoffmann-La Roche Ltd

Contents

1. INTRODUCTION

- 1.1 Report Guidance
- 1.2 Market Segmentation

2. EXECUTIVE SUMMARY

- 2.1 Analyst Market Outlook

3. RESEARCH METHODOLOGY

- 3.1 Secondary Research
- 3.2 Primary Research
 - 3.2.1 Hypothesis formulation:
 - 3.2.2 Macro-economic factor analysis:
 - 3.2.3 Developing base number:
 - 3.2.4 Data Triangulation:
 - 3.2.5 Country level data:
- 3.3 Assumptions and Limitations

4. ANTI-OBESITY DRUGS MARKET LANDSCAPE

- 4.1 Overview
- 4.2 PEST Analysis

5. ANTI-OBESITY DRUGS MARKET – KEY MARKET DYNAMICS

- 5.1 Anti-Obesity Drugs Market – Key Market Dynamics
- 5.2 Market Drivers
 - 5.2.1 Mounting Prevalence of Obesity
 - 5.2.2 Increased Awareness and Demand for Weight Management Solutions
- 5.3 Market Restraints
 - 5.3.1 Side Effects and Safety Concerns
- 5.4 Market Opportunities
 - 5.4.1 Expansion in Emerging Economies
- 5.5 Future Trends
 - 5.5.1 Precision Medicine and Personalized Anti-Obesity Drug Regimens

5.6 Impact of Drivers and Restraints:

6. ANTI-OBESITY DRUGS MARKET – GLOBAL MARKET ANALYSIS

6.1 Anti-Obesity Drugs Market Revenue (US\$ Million), 2021–2031

6.2 Anti-Obesity Drugs Market Forecast Analysis

7. ANTI-OBESITY DRUGS MARKET ANALYSIS – BY TYPE

7.1 Prescription Drugs

7.1.1 Overview

7.1.2 Prescription Drugs: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

7.2 OTC Drugs

7.2.1 Overview

7.2.2 OTC Drugs: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

8. ANTI-OBESITY DRUGS MARKET ANALYSIS – BY DRUG CLASS

8.1 GLP-1 Agonist

8.1.1 Overview

8.1.2 GLP-1 Agonist: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

8.2 Lipase Inhibitors

8.2.1 Overview

8.2.2 Lipase Inhibitors: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

8.3 MC4R agonist

8.3.1 Overview

8.3.2 MC4R agonist: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

8.4 Others

8.4.1 Overview

8.4.2 Others: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

9. ANTI-OBESITY DRUGS MARKET ANALYSIS – BY APPLICATION

9.1 Appetite Suppression

9.1.1 Overview

9.1.2 Appetite Suppression: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

9.2 Inhibition of Fat Absorption or Digestive Enzymes

9.2.1 Overview

9.2.2 Inhibition of Fat Absorption or Digestive Enzymes: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

9.3 Metabolic Enhancement

9.3.1 Overview

9.3.2 Metabolic Enhancement: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

9.4 Combination

9.4.1 Overview

9.4.2 Combination: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

10. ANTI-OBESITY DRUGS MARKET ANALYSIS – BY ROUTE OF ADMINISTRATION

10.1 Oral

10.1.1 Overview

10.1.2 Oral: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

10.2 Parenteral

10.2.1 Overview

10.2.2 Parenteral: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

11. ANTI-OBESITY DRUGS MARKET ANALYSIS – BY DISTRIBUTION CHANNEL

11.1 Hospital Pharmacies

11.1.1 Overview

11.1.2 Hospital Pharmacies: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

11.2 Online Channel

11.2.1 Overview

11.2.2 Online Channel: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

11.3 Retail Pharmacies

11.3.1 Overview

11.3.2 Retail Pharmacies: Anti-Obesity Drugs Market – Revenue and Forecast to 2031 (US\$ Million)

12. ANTI-OBESITY DRUGS MARKET – GEOGRAPHICAL ANALYSIS

12.1 Overview

12.2 North America

12.2.1 North America Anti-Obesity Drugs Market Overview

12.2.2 North America: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US\$ Million)

12.2.3 North America: Anti-Obesity Drugs Market Breakdown, by Type

12.2.3.1 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Type

12.2.4 North America: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.2.4.1 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Drug Class

12.2.4.1.1 North America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.2.5 North America: Anti-Obesity Drugs Market Breakdown, by Application

12.2.5.1 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Application

12.2.6 North America: Anti-Obesity Drugs Market Breakdown, by Route Of Administration

12.2.6.1 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Route Of Administration

12.2.7 North America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.2.7.1 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Distribution Channel

12.2.8 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country

12.2.8.1 North America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country

12.2.8.2 United States: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.2.8.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Type

12.2.8.2.2 United States: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.2.8.2.2.1 United States: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.2.8.2.3 United States: Anti-Obesity Drugs Market Breakdown, by Application

12.2.8.2.4 United States: Anti-Obesity Drugs Market Breakdown, by Route Of

Administration

12.2.8.2.5 United States: Anti-Obesity Drugs Market Breakdown, by Distribution

Channel

12.2.8.3 Canada: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031
(US\$ Million)

12.2.8.3.1 Canada: Anti-Obesity Drugs Market Breakdown, by Type

12.2.8.3.2 Canada: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.2.8.3.2.1 Canada: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.2.8.3.3 Canada: Anti-Obesity Drugs Market Breakdown, by Application

12.2.8.3.4 Canada: Anti-Obesity Drugs Market Breakdown, by Route Of

Administration

12.2.8.3.5 Canada: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.2.8.4 Mexico: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031
(US\$ Million)

12.2.8.4.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Type

12.2.8.4.2 Mexico: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.2.8.4.2.1 Mexico: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.2.8.4.3 Mexico: Anti-Obesity Drugs Market Breakdown, by Application

12.2.8.4.4 Mexico: Anti-Obesity Drugs Market Breakdown, by Route Of

Administration

12.2.8.4.5 Mexico: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.3 Europe

12.3.1 Europe Anti-Obesity Drugs Market Overview

12.3.2 Europe: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US\$ Million)

12.3.3 Europe: Anti-Obesity Drugs Market Breakdown, by Type

12.3.3.1 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by
Type

12.3.4 Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.3.4.1 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by
Drug Class

12.3.4.1.1 Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.3.5 Europe: Anti-Obesity Drugs Market Breakdown, by Application

12.3.5.1 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by
Application

12.3.6 Europe: Anti-Obesity Drugs Market Breakdown, by Route Of Administration

12.3.6.1 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by
Route Of Administration

12.3.7 Europe: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.3.7.1 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by

Distribution Channel

12.3.8 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country

12.3.8.1 Europe: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country

12.3.8.2 Germany: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.3.8.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Type

12.3.8.2.2 Germany: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.3.8.2.2.1 Germany: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.3.8.2.3 Germany: Anti-Obesity Drugs Market Breakdown, by Application

12.3.8.2.4 Germany: Anti-Obesity Drugs Market Breakdown, by Route Of

Administration

12.3.8.2.5 Germany: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.3.8.3 United Kingdom: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.3.8.3.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Type

12.3.8.3.2 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.3.8.3.2.1 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Glp-1

Agonist

12.3.8.3.3 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Application

12.3.8.3.4 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Route Of

Administration

12.3.8.3.5 United Kingdom: Anti-Obesity Drugs Market Breakdown, by Distribution

Channel

12.3.8.4 France: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.3.8.4.1 France: Anti-Obesity Drugs Market Breakdown, by Type

12.3.8.4.2 France: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.3.8.4.2.1 France: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.3.8.4.3 France: Anti-Obesity Drugs Market Breakdown, by Application

12.3.8.4.4 France: Anti-Obesity Drugs Market Breakdown, by Route Of

Administration

12.3.8.4.5 France: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.3.8.5 Spain: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.3.8.5.1 Spain: Anti-Obesity Drugs Market Breakdown, by Type

12.3.8.5.2 Spain: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.3.8.5.2.1 Spain: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.3.8.5.3 Spain: Anti-Obesity Drugs Market Breakdown, by Application

12.3.8.5.4 Spain: Anti-Obesity Drugs Market Breakdown, by Route Of

Administration

12.3.8.5.5 Spain: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.3.8.6 Italy: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.3.8.6.1 Italy: Anti-Obesity Drugs Market Breakdown, by Type

12.3.8.6.2 Italy: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.3.8.6.2.1 Italy: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.3.8.6.3 Italy: Anti-Obesity Drugs Market Breakdown, by Application

12.3.8.6.4 Italy: Anti-Obesity Drugs Market Breakdown, by Route Of Administration

12.3.8.6.5 Italy: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.3.8.7 Rest of Europe: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.3.8.7.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Type

12.3.8.7.2 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.3.8.7.2.1 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.3.8.7.3 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Application

12.3.8.7.4 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Route Of

Administration

12.3.8.7.5 Rest of Europe: Anti-Obesity Drugs Market Breakdown, by Distribution

Channel

12.4 Asia Pacific

12.4.1 Asia Pacific Anti-Obesity Drugs Market Overview

12.4.2 Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US\$ Million)

12.4.3 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Type

12.4.3.1 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Type

12.4.4 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.4.4.1 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Drug Class

12.4.4.1.1 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.4.5 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Application

12.4.5.1 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Application

12.4.6 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Route Of Administration

12.4.6.1 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Route Of Administration

12.4.7 Asia Pacific: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.4.7.1 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Distribution Channel

12.4.8 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country

12.4.8.1 Asia Pacific: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country

12.4.8.2 China: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.4.8.2.1 China: Anti-Obesity Drugs Market Breakdown, by Type

12.4.8.2.2 China: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.4.8.2.2.1 China: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.4.8.2.3 China: Anti-Obesity Drugs Market Breakdown, by Application

12.4.8.2.4 China: Anti-Obesity Drugs Market Breakdown, by Route Of

Administration

12.4.8.2.5 China: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.4.8.3 Japan: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.4.8.3.1 Japan: Anti-Obesity Drugs Market Breakdown, by Type

12.4.8.3.2 Japan: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.4.8.3.2.1 Japan: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.4.8.3.3 Japan: Anti-Obesity Drugs Market Breakdown, by Application

12.4.8.3.4 Japan: Anti-Obesity Drugs Market Breakdown, by Route Of

Administration

12.4.8.3.5 Japan: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.4.8.4 India: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.4.8.4.1 India: Anti-Obesity Drugs Market Breakdown, by Type

12.4.8.4.2 India: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.4.8.4.2.1 India: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.4.8.4.3 India: Anti-Obesity Drugs Market Breakdown, by Application

12.4.8.4.4 India: Anti-Obesity Drugs Market Breakdown, by Route Of Administration

12.4.8.4.5 India: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.4.8.5 Australia: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.4.8.5.1 Australia: Anti-Obesity Drugs Market Breakdown, by Type

12.4.8.5.2 Australia: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.4.8.5.2.1 Australia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.4.8.5.3 Australia: Anti-Obesity Drugs Market Breakdown, by Application

- 12.4.8.5.4 Australia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
- 12.4.8.5.5 Australia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.4.8.6 South Korea: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)
 - 12.4.8.6.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Type
 - 12.4.8.6.2 South Korea: Anti-Obesity Drugs Market Breakdown, by Drug Class
 - 12.4.8.6.2.1 South Korea: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
 - 12.4.8.6.3 South Korea: Anti-Obesity Drugs Market Breakdown, by Application
 - 12.4.8.6.4 South Korea: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
 - 12.4.8.6.5 South Korea: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.4.8.7 Rest of APAC: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)
 - 12.4.8.7.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Type
 - 12.4.8.7.2 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Drug Class
 - 12.4.8.7.2.1 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
 - 12.4.8.7.3 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Application
 - 12.4.8.7.4 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Route Of Administration
 - 12.4.8.7.5 Rest of APAC: Anti-Obesity Drugs Market Breakdown, by Distribution Channel
- 12.5 Middle East and Africa
 - 12.5.1 Middle East and Africa Anti-Obesity Drugs Market Overview
 - 12.5.2 Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US\$ Million)
 - 12.5.3 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type
 - 12.5.3.1 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Type
 - 12.5.4 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class
 - 12.5.4.1 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Drug Class
 - 12.5.4.1.1 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist
 - 12.5.5 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application
 - 12.5.5.1 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Application

12.5.6 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration

12.5.6.1 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Route Of Administration

12.5.7 Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.5.7.1 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Distribution Channel

12.5.8 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country

12.5.8.1 Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country

12.5.8.2 Saudi Arabia: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.5.8.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Type

12.5.8.2.2 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.5.8.2.2.1 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.5.8.2.3 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Application

12.5.8.2.4 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Route Of Administration

12.5.8.2.5 Saudi Arabia: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.5.8.3 South Africa: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.5.8.3.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Type

12.5.8.3.2 South Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.5.8.3.2.1 South Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.5.8.3.3 South Africa: Anti-Obesity Drugs Market Breakdown, by Application

12.5.8.3.4 South Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration

12.5.8.3.5 South Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.5.8.4 United Arab Emirates: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.5.8.4.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Type

12.5.8.4.2 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.5.8.4.2.1 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by

Glp-1 Agonist

12.5.8.4.3 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Application

12.5.8.4.4 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Route Of Administration

12.5.8.4.5 United Arab Emirates: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.5.8.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.5.8.5.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Type

12.5.8.5.2 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.5.8.5.2.1 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.5.8.5.3 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Application

12.5.8.5.4 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Route Of Administration

12.5.8.5.5 Rest of Middle East and Africa: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.6 South and Central America

12.6.1 South and Central America Anti-Obesity Drugs Market Overview

12.6.2 South and Central America: Anti-Obesity Drugs Market – Revenue, 2021–2031 (US\$ Million)

12.6.3 South and Central America: Anti-Obesity Drugs Market Breakdown, by Type

12.6.3.1 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Type

12.6.4 South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.6.4.1 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Drug Class

12.6.4.1.1 South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.6.5 South and Central America: Anti-Obesity Drugs Market Breakdown, by Application

12.6.5.1 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Application

12.6.6 South and Central America: Anti-Obesity Drugs Market Breakdown, by Route

Of Administration

12.6.6.1 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Route Of Administration

12.6.7 South and Central America: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.6.7.1 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Distribution Channel

12.6.8 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country

12.6.8.1 South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast Analysis – by Country

12.6.8.2 Brazil: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.6.8.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Type

12.6.8.2.2 Brazil: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.6.8.2.2.1 Brazil: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.6.8.2.3 Brazil: Anti-Obesity Drugs Market Breakdown, by Application

12.6.8.2.4 Brazil: Anti-Obesity Drugs Market Breakdown, by Route Of Administration

12.6.8.2.5 Brazil: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.6.8.3 Argentina: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.6.8.3.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Type

12.6.8.3.2 Argentina: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.6.8.3.2.1 Argentina: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.6.8.3.3 Argentina: Anti-Obesity Drugs Market Breakdown, by Application

12.6.8.3.4 Argentina: Anti-Obesity Drugs Market Breakdown, by Route Of

Administration

12.6.8.3.5 Argentina: Anti-Obesity Drugs Market Breakdown, by Distribution Channel

12.6.8.4 Rest of South and Central America: Anti-Obesity Drugs Market – Revenue and Forecast, 2021–2031 (US\$ Million)

12.6.8.4.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Type

12.6.8.4.2 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Drug Class

12.6.8.4.2.1 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Glp-1 Agonist

12.6.8.4.3 Rest of South and Central America: Anti-Obesity Drugs Market Breakdown, by Application

12.6.8.4.4 Rest of South and Central America: Anti-Obesity Drugs Market
Breakdown, by Route Of Administration

12.6.8.4.5 Rest of South and Central America: Anti-Obesity Drugs Market
Breakdown, by Distribution Channel

13. INDUSTRY LANDSCAPE

13.1 Overview

13.2 New Product Development/Approval

13.3 Other Business Strategies

14. COMPANY PROFILES

14.1 Novo Nordisk AS

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.2 Eli Lilly and Co

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 GSK Plc

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.4 Rhythm Pharmaceuticals Inc

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 Currax Pharmaceuticals LLC.

- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments

14.6 VIVUS LLC

- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments

14.7 AdvaCare Pharma USA LLC

- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis

15. APPENDIX

15.1 About The Insight Partners

15.2 Glossary of Terms

List Of Tables

LIST OF TABLES

Table 1. Anti-Obesity Drugs Market Segmentation

Table 2. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million)

Table 3. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million)

Table 4. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 5. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 6. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 7. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 8. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 9. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 10. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 11. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 12. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 13. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 14. Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 15. Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 16. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 17. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 18. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 19. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 20. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$

Million) – by Glp-1 Agonist

Table 21. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 22. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 23. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 24. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 25. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 26. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 27. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 28. North America: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Country

Table 29. North America: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Country

Table 30. United States: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 31. United States: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 32. United States: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 33. United States: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 34. United States: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 35. United States: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 36. United States: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 37. United States: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 38. United States: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 39. United States: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 40. United States: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 41. United States: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 42. Canada: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 43. Canada: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 44. Canada: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 45. Canada: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 46. Canada: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 47. Canada: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 48. Canada: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 49. Canada: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 50. Canada: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 51. Canada: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 52. Canada: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 53. Canada: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 54. Mexico: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 55. Mexico: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 56. Mexico: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 57. Mexico: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 58. Mexico: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 59. Mexico: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$

Million) – by Glp-1 Agonist

Table 60. Mexico: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 61. Mexico: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 62. Mexico: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 63. Mexico: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 64. Mexico: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 65. Mexico: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 66. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 67. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 68. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 69. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 70. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 71. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 72. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 73. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 74. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 75. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 76. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 77. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 78. Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Country

Table 79. Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Country

Table 80. ADULT OBESITY IN 2030

Table 81. CHILD OBESITY IN 2030

Table 82. Germany: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 83. Germany: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 84. Germany: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 85. Germany: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 86. Germany: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 87. Germany: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 88. Germany: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 89. Germany: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 90. Germany: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 91. Germany: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 92. Germany: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 93. Germany: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 94. United Kingdom: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 95. United Kingdom: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 96. United Kingdom: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 97. United Kingdom: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 98. United Kingdom: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 99. United Kingdom: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031

(US\$ Million) – by Glp-1 Agonist

Table 100. United Kingdom: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 101. United Kingdom: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 102. United Kingdom: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 103. United Kingdom: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 104. United Kingdom: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 105. United Kingdom: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 106. France: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 107. France: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 108. France: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 109. France: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 110. France: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 111. France: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 112. France: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 113. France: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 114. France: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 115. France: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 116. France: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 117. France: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 118. ADULT OBESITY IN 2030

Table 119. CHILD OBESITY IN 2030

Table 120. Spain: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 121. Spain: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 122. Spain: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 123. Spain: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 124. Spain: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 125. Spain: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 126. Spain: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 127. Spain: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 128. Spain: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 129. Spain: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 130. Spain: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 131. Spain: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 132. Italy: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 133. Italy: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 134. Italy: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 135. Italy: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 136. Italy: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 137. Italy: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 138. Italy: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 139. Italy: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$

Million) – by Application

Table 140. Italy: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 141. Italy: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 142. Italy: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 143. Italy: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 144. Rest of Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 145. Rest of Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 146. Rest of Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 147. Rest of Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 148. Rest of Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 149. Rest of Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 150. Rest of Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 151. Rest of Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 152. Rest of Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 153. Rest of Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 154. Rest of Europe: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 155. Rest of Europe: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 156. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 157. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 158. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 159. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 160. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 161. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 162. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 163. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 164. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 165. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 166. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 167. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 168. Asia Pacific: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Country

Table 169. Asia Pacific: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Country

Table 170. China: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 171. China: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 172. China: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 173. China: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 174. China: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 175. China: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 176. China: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 177. China: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 178. China: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by

Route Of Administration

Table 179. China: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 180. China: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 181. China: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 182. ADULT OBESITY IN 2030

Table 183. CHILD OBESITY IN 2030

Table 184. Japan: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 185. Japan: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 186. Japan: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 187. Japan: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 188. Japan: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 189. Japan: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 190. Japan: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 191. Japan: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 192. Japan: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 193. Japan: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 194. Japan: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 195. Japan: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 196. India: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 197. India: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 198. India: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 199. India: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 200. India: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 201. India: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 202. India: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 203. India: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 204. India: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 205. India: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 206. India: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 207. India: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 208. Australia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 209. Australia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 210. Australia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 211. Australia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 212. Australia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 213. Australia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 214. Australia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 215. Australia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 216. Australia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 217. Australia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 218. Australia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) –

by Distribution Channel

Table 219. Australia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 220. South Korea: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 221. South Korea: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 222. South Korea: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 223. South Korea: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 224. South Korea: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 225. South Korea: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 226. South Korea: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 227. South Korea: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 228. South Korea: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 229. South Korea: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 230. South Korea: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 231. South Korea: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 232. Rest of APAC: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 233. Rest of APAC: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 234. Rest of APAC: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 235. Rest of APAC: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 236. Rest of APAC: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 237. Rest of APAC: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 238. Rest of APAC: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 239. Rest of APAC: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 240. Rest of APAC: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 241. Rest of APAC: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 242. Rest of APAC: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 243. Rest of APAC: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 244. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 245. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 246. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 247. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 248. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 249. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 250. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 251. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 252. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 253. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 254. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 255. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 256. Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Country

Table 257. Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast,

2025–2031 (US\$ Million) – by Country

Table 258. Saudi Arabia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 259. Saudi Arabia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 260. Saudi Arabia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 261. Saudi Arabia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 262. Saudi Arabia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 263. Saudi Arabia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 264. Saudi Arabia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 265. Saudi Arabia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 266. Saudi Arabia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 267. Saudi Arabia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 268. Saudi Arabia: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 269. Saudi Arabia: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 270. ADULT OBESITY IN 2030

Table 271. CHILD OBESITY IN 2030

Table 272. South Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 273. South Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 274. South Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 275. South Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 276. South Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 277. South Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 278. South Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 279. South Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 280. South Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 281. South Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 282. South Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 283. South Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 284. United Arab Emirates: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Type

Table 285. United Arab Emirates: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 286. United Arab Emirates: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 287. United Arab Emirates: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 288. United Arab Emirates: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 289. United Arab Emirates: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 290. United Arab Emirates: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 291. United Arab Emirates: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 292. United Arab Emirates: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 293. United Arab Emirates: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

Table 294. United Arab Emirates: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Distribution Channel

Table 295. United Arab Emirates: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Distribution Channel

Table 296. ADULT OBESITY IN 2030

Table 297. CHILD OBESITY IN 2030

Table 298. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue,

2021–2024 (US\$ Million) – by Type

Table 299. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Type

Table 300. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Drug Class

Table 301. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Drug Class

Table 302. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Glp-1 Agonist

Table 303. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Glp-1 Agonist

Table 304. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Application

Table 305. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Application

Table 306. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue, 2021–2024 (US\$ Million) – by Route Of Administration

Table 307. Rest of Middle East and Africa: Anti-Obesity Drugs Market – Revenue Forecast, 2025–2031 (US\$ Million) – by Route Of Administration

I would like to order

Product name: Anti-obesity Drugs Market Size and Forecast (2021 - 2031), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Prescription and OTC), Drug Class (GLP-1 Agonist, Lipase Inhibitors, MC4R agonist, and others), Application (Appetite Suppression, Inhibition of Fat Absorption/Digestive Enzymes, Metabolic Enhancement, and Combination), Route of Administration (Oral and Parenteral), and Distribution Channel (Hospital Pharmacies, Online Channel, and Retail Pharmacies), and Geography

Product link: <https://marketpublishers.com/r/A13C6496AF0CEN.html>

Price: US\$ 4,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A13C6496AF0CEN.html>